Table 4 Multivariate analysis of survival and AML evolution

From: Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution

Variables Categories Survival
   HR (95% CI) P-value
Age    
  <63
  63 2.0 (1.4–3.0) 0.001
Cytopenias    0.001
  0
  1 1.4 (0.6–3.2) 0.38
  2 1.8 (0.8–4.2) 0.14
  3 3.7 (15.4–8.7) 0.003
Blast cell percentage    0.0001
  <5
  5–10 4.0 (2.3–6.9) 0.001
  11–20 4.4 (2.7–7.3) 0.001
  21–30 6.9 (4.0–12.1) 0.001
Mod. IPSS cytogenetic categoriesa    0.0001
  Good
  Intermediate 1.8 (1.2–2.9) 0.006
  adel(7) (q31q35) 1.9 (0.7–4.7) 0.16
  Poor 6.7 (3.8–11.9) 0.001
   MDS/AML progression
   HR (95% CI) P-value
Cytopenias    0.07
  0
  1 1.7 (0.7–4.0) 0.21
  2 2.0 (0.9–4.7) 0.09
  3 2.9 (1.2–7.0) 0.01
Blast cell percentage    0.0001
  <5
  5–10 2.4 (1.2–4.7) 0.009
  11–20 5.0 (3.0–8.7) 0.001
  21–30 6.2 (3.4–11.4) 0.001
Mod. IPSS cytogenetic categoriesa    0.0001
  Good
  Intermediate 1.8 (1.1–3.0) 0.012
  cdel(7) (q31q35) 3.1 (1.3–6.8) 0.006
  Poor 3.8 (2.0–7.1) 0.001
  1. Mod. IPSS cytogenetic categories.
  2. aGood=normal, −Y, del(5q), del(20q) only; Intermediate=+8, various single and double defects; del(7) (q31q35) is considered as a new entity, apart from the ‘Poor-risk’ category=complex (three defects), −7.
  3. IPSS intermediate cytogenetic category vs del(7) (q31q35): HR(95% CI)=0.9 (0.4–2.4) with P=0.96; IPSS poor cytogenetic category vs del(7) (q31q35): HR(95% CI)=3.5 (1.3–9.2) with P=0.009.
  4. cIPSS intermediate cytogenetic category vs del(7) (q31q35): HR(95% CI)=1.6 (0.7–3.5) with P=0.19; IPSS poor cytogenetic category vs del(7) (q31q35): HR(95% CI)=1.2 (0.5–2.9) with P=0.63.